Literature DB >> 12191851

Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other synthetic progestins.

Hiroshi Tatsumi1, Jo Kitawaki, Kazunori Tanaka, Tetsuya Hosoda, Hideo Honjo.   

Abstract

OBJECTIVES: Monocyte adhesion to endothelial cells is an important initial event at the onset of atherosclerosis. It is partially mediated by the expression of adhesion molecules on the endothelial cell surface. While estrogens inhibit the development of atherosclerosis, the effect of co-administered progestin remains controversial. We examined the effect of progestins on cytokine-stimulated human umbilical venous endothelial cell (HUVEC) expression of adhesion molecules.
METHODS: In HUVECs, mRNA expression of progesterone receptors (PRs) and androgen receptors (AR) was determined by RT-PCR. HUVECs were stimulated by interleukin-1beta (IL-1beta) for 24 h with or without various steroids, and then the cell-surface expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) was semiquantified by ELISA.
RESULTS: In all preparations of HUVECs used in this study, RT-PCR confirmed mRNA expression of both isoforms of PR, PR-A and PR-B, as well as AR. Addition of progesterone (10(-10)-10(-7) M) or dienogest (DNG) (10(-10)-10(-8) M) did not affect IL-1beta-stimulated ICAM-1 or VCAM-1 expression. In contrast, medroxyprogesterone acetate, norethindrone acetate and levonorgestrel (10(-10)-10(-8) M) dose-dependently increased cell adhesion molecules. The progestin-induced increase was blocked by the concomitant addition of mifepristone, a PR antagonist, but not by hydroxyflutamide, an AR antagonist, indicating that the progestin stimulation was mediated predominantly via PR.
CONCLUSIONS: These results suggest that DNG, unlike other synthetic progestins, lacks stimulation of cell adhesion molecules. For the prevention of atherosclerosis, estrogen in combination with DNG may be a suitable regimen in hormone replacement therapy in postmenopausal women. Copyright 2002 Elsevier Science Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12191851     DOI: 10.1016/s0378-5122(02)00157-3

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  4 in total

Review 1.  Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.

Authors:  Frank Z Stanczyk; Janet P Hapgood; Sharon Winer; Daniel R Mishell
Journal:  Endocr Rev       Date:  2012-12-13       Impact factor: 19.871

2.  Human umbilical vascular endothelial cells express estrogen receptor beta (ERbeta) and progesterone receptor A (PR-A), but not ERalpha and PR-B.

Authors:  Bettina Toth; Gitti Saadat; Alrun Geller; Christoph Scholz; Sandra Schulze; Klaus Friese; Udo Jeschke
Journal:  Histochem Cell Biol       Date:  2008-04-18       Impact factor: 4.304

3.  Dienogest in long-term treatment of endometriosis.

Authors:  Adolf E Schindler
Journal:  Int J Womens Health       Date:  2011-07-06

4.  Equilin in conjugated equine estrogen increases monocyte-endothelial adhesion via NF-κB signaling.

Authors:  Fumitake Ito; Taisuke Mori; Yosuke Tarumi; Hiroyuki Okimura; Hisashi Kataoka; Yukiko Tanaka; Akemi Koshiba; Jo Kitawaki
Journal:  PLoS One       Date:  2019-01-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.